Zeev's Turnips Patch-No Politics (ZEEV)

[mainehiker]

hmm... maybe he will just say,
as he did yesterday "im baffled"
(or admit something!)

(and for alex, im not blaming him or anybody)

ARIAD To Host Analyst Conference Call June 15, 2004; Audio May
Business Wire - June 09, 2004 07:30

CAMBRIDGE, Mass., Jun 9, 2004 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it will host a conference call for biotechnology investment analysts on Tuesday, June 15, 2004, at 11 a.m. (ET). The Company's senior management will discuss the clinical results of its lead oncology product candidate, AP23573, which were summarized in a press release issued June 7, and its plans for advancing the clinical development of this product candidate, which will be released before the market opens on June 15.

Biotechnology industry analysts associated with investment banks and institutional funds are invited to call ARIAD's investor relations office at 610-407-9260 to obtain information that will enable them to participate in the Q&A of the conference call.

A direct link to a live audio webcast of the conference call can be accessed at ARIAD's website (http://www.ariad.com/investor) by clicking on this link. An archived audio webcast also will be available beginning approximately two hours after completion of the conference call until 5:00 p.m. (ET) on Tuesday, June 22, 2004. To ensure a timely connection to the live webcast, it is recommended that participants register at least fifteen minutes prior to the scheduled webcast.

Alternatively, the conference call can be heard by calling 888-842-0024 (U.S.) or 617-801-9702 (international) and providing the pass code number 52889596. Telephone replay will be available beginning approximately two hours after completion of the conference call until 5:00 p.m. (ET) on Tuesday, June 22, 2004. To access the replay, please call 888-286-8010 (U.S.) or 617-801-6888 (international) and provide the pass code number 89039170

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD also has an exclusive license to pioneering technology and patents related to certain NF-(kappa)B treatment methods, and the discovery and development of drugs to regulate NF-(kappa)B cell-signaling activity.

Additional information about ARIAD can be found on the web at http://www.ariad.com.





--------------------------------------------------------------------------------







News provided by Dow Jones NewswiresSM, PR News Wire™ and Business Wire™. Dow Jones Newswires is a service mark of Dow Jones & Company. PR News Wire is a Trademark of PR Newswire Association, Inc. Business Wire is a registered trademark and service mark of Business Wire.

Ameritrade is not responsible for the quality and suitability of third party financial or investment information or services. Please consult other sources of information and consider your individual financial position and goals before making an investment decision.
Ameritrade, Division of Ameritrade, Inc., member NASD/SIPC. Ameritrade and Ameritrade logos are trademarks or registered trademarks of Ameritrade IP Company, Inc. 2002 Ameritrade IP Company, Inc. All rights reserved. Used with permission.